Home › Biliary Tract Cancer › Maryland
Biliary Tract Cancer clinical trials in Maryland
11 studies for Biliary Tract Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 2 to 100 · All sexes · Updated Oct 2, 2026 · NCT01950572A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07221253SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
- United Theranostics, Glen Burnie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07812805Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Towson
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 19, 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- National Institutes of Health, Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- The John Hopkins Hospital, Baltimore
- Maryland Oncology Hematology- Columbia, Rockville
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
- SKCCC Johns Hopkins Medical Institution, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06564623Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- University of Maryland Medical Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT05733598A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Mar 24, 2026 · NCT05849480Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
RecruitingPhase 1
Ages 21 and older · All sexes · Updated Dec 10, 2025 · NCT06546969Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- SKCCC Johns Hopkins, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 3, 2025 · NCT06001658From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.